04:29:26 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMid Cap Copenhagen
IndustriLäkemedel & Handel
Bavarian Nordic är verksamma inom biokemi. Idag är bolaget specialiserade inom utveckling, produktion och distribution av vaccin mot infektionssjukdomar i samband med cancerbehandling. Utöver huvudverksamheten framställs även vacciner mot allvarliga sjukdomar som ebola och livmoderhalscancer. Störst verksamhet återfinns inom Europa och Nordamerika, med huvudkontoret beläget i Kvistgaard.


2022-11-09 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-09 Kvartalsrapport 2022-Q1
2022-04-05 Årsstämma 2022
2022-03-04 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-27 Kvartalsrapport 2021-Q1
2021-04-21 Ordinarie utdelning BAVA 0.00 DKK
2021-04-20 Årsstämma 2021
2021-03-12 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-15 Ordinarie utdelning BAVA 0.00 DKK
2020-06-12 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-27 Extra Bolagsstämma 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-22 Kvartalsrapport 2019-Q1
2019-04-25 Ordinarie utdelning BAVA 0.00 DKK
2019-04-24 Årsstämma 2019
2019-03-21 Bokslutskommuniké 2018
2018-11-09 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-24 Kvartalsrapport 2018-Q1
2018-04-18 Ordinarie utdelning BAVA 0.00 DKK
2018-04-17 Årsstämma 2018
2018-03-12 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-04 Kvartalsrapport 2017-Q1
2017-04-26 Ordinarie utdelning BAVA 0.00 DKK
2017-04-25 Årsstämma 2017
2017-03-15 Bokslutskommuniké 2016
2016-11-09 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-13 Kvartalsrapport 2016-Q1
2016-04-21 Ordinarie utdelning BAVA 0.00 DKK
2016-04-20 Årsstämma 2016
2016-03-07 Bokslutskommuniké 2015
2015-11-03 Kvartalsrapport 2015-Q3
2015-08-25 Kvartalsrapport 2015-Q2
2015-05-05 Kvartalsrapport 2015-Q1
2015-04-24 Ordinarie utdelning BAVA 0.00 DKK
2015-04-23 Årsstämma 2015
2015-03-11 Bokslutskommuniké 2014
2014-04-25 Ordinarie utdelning BAVA 0.00 DKK
2013-04-18 Ordinarie utdelning BAVA 0.00 DKK
2012-04-17 Ordinarie utdelning BAVA 0.00 DKK
2011-04-27 Ordinarie utdelning
2010-04-28 Ordinarie utdelning
2020-09-01 08:00:00

Martinsried, Germany, September 1, 2020 – Bavarian Nordic today announced the initiation of full commercial operations in Germany only nine months after completing the acquisition of the manufacturing and global rights to Encepur® (Tick-Borne Encephalitis vaccine) and Rabipur® (rabies vaccine) from GlaxoSmithKline plc (GSK). This ensures complete distribution and marketing of Encepur and Rabipur in Germany, a major milestone in the commercial transformation at Bavarian Nordic, advancing the company’s robust infectious disease vaccines franchise.

 “At Bavarian Nordic, we have a compelling infrastructure that aligns with the critical vaccine market needs from basic research and development to commercial operations, manufacturing and distribution,” stated Paul Chaplin, President and CEO of Bavarian Nordic. “We are proud of the speed at which we managed to establish our commercial presence in Germany enabling the full commercial support of Encepur and Rabipur.”

Bavarian Nordic’s concentrated focus in vaccines is exemplified through their proprietary and innovative MVA-BN technology, which drives research and development as well as commercialization of life-saving vaccines including two approved vaccines: JYNNEOS® for smallpox and monkeypox (IMVANEX® in Europe) and MVABEA® for Ebola. Clinically, the technology is currently being investigated across several indications, including Respiratory Syncytial Virus (RSV), cancer immunotherapies, and Equine Encephalitis.

Established more than 25 years ago, the foundation of Bavarian Nordic’s research is deeply rooted in Germany, which still is homing the company’s scientific advances. Based in Martinsried, near Munich, the state-of-the-art research facilities are now supplemented by a fully-fledged commercial organization, supporting the German market for Encepur and Rabipur.

Expanding where there are significant needs, the company continues to seek scientific collaborations that address the most critical world challenges in vaccines.  In May 2020, Bavarian Nordic entered into an exclusive agreement with AdaptVac to advance a potential COVID-19 vaccine into clinical trials. Bavarian Nordic also has a history of supply reliability and dedication that has led to key distributions advancements, including a long-term partnership with the U.S. Government, most recently supplying smallpox vaccine to the U.S. Strategic National Stockpile for emergency use.

“Our impressive talent base made the quick transition to commercialization possible and we will continue to do what we do best; develop and distribute life-saving vaccines to protect people at risk,” stated Jean-Christophe May, Executive Vice President and Chief Commercial Officer. “We celebrate this milestone as we continue to expand our commercial footprint to include more than 30 countries around the world, ensuring a reliable supply of our vaccines, wherever and whenever they are needed.”

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine; Encepur® against tick-borne encephalitis, Rabipur® against rabies and a vaccine against Ebola (ZABDENO® and MVABEA®) that has been licensed to Janssen. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system. For more information visit www.bavarian-nordic.com.

Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43